BackSunny Pharmtech Overview

Sunny Pharmtech Profit Margin

Latest profit margin for Sunny Pharmtech: -113.58% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-204.33%
↓ 41.39% YoY

As of Jun 2026

Annual Profit Margin (TTM)

-113.58%
↓ 491.28% YoY

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Sunny Pharmtech (6676.TWO) FAQ

The latest profit margin for 6676.TWO is -113.58% as of June 2026. That compares with -19.21% in the prior-year period — down 491.3% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Sunny Pharmtech's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6676.TWO's profit margin moved from -19.21% to -113.58% — a 491.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sunny Pharmtech's valuation or profitability profile.

Against Healthcare companies, 6676.TWO currently prints -113.58% for profit margin, while the sector average sits near 17.63%. That is roughly 744.3% below the sector mean. Large gaps often invite a closer look at Sunny Pharmtech's growth, margins, and balance sheet.

Profit Margin shows how effectively Sunny Pharmtech converts resources into returns. At -113.58%, 6676.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -19.21% in the prior-year period — down 491.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 6676.TWO's profit margin (-113.58%), review year-over-year change from -19.21%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.